Pharmacologic medical<unk> es for<unk>  and<unk>  include corticosteroids and disease-modifying antirheumatic drugs (DMARDs). Patients with<unk>  and<unk>  might require long-term treatment. However, if there are no disease flares during the course of the taper, glucocorticoids could be discontinued at 9 to 12 months. DMARDs might be discontinued at 6 months. Patients with recurrent flare of<unk>  and<unk>  require higher dose of prednisone, adding or increasing dose of methotrexate or azathioprine. Rituximab, IVIg, and mycophenolate mofetil might be used in resistant diseases.
Polymyositis and dermatomyositis medical therapy
Polymyalgia rheumatica medical therapy
Adrenoleukodystrophy medical therapy
Statin induced myopathy medical therapy
Scleroderma medical therapy
Guillain-Barré syndrome physical therapy
Peripheral neuropathy medical therapy
Sjögren's syndrome medical therapy